Familial Mediterranean Fever Pharmaceuticals Market Report 2025

The familial mediterranean fever pharmaceuticals market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.72 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to rise in the disease prevalence, rise in the migration, rise in the geriatric population, increasing cases of genetic aberrations within the MEFV gene, and rise in genetic mutation.

The familial mediterranean fever pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increase in the adoption of advanced cancer therapeutic options, growing interest in gene therapy and biologics, rise in adoption of advanced therapy, inflating utilization of effective medications, and widespread adoption of supportive therapies. Major trends in the forecast period include advancements in treatment, introduction of newer drug classes, collaboration between academic institutions, research organizations, and pharmaceutical companies, adaptation of new therapeutics, and development in technology.

The forecast of 5.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder U.S. autoinflammatory disease management by inflating prices of colchicine APIs and genetic testing kits sourced from Israel and Turkey, resulting in delayed treatment initiation and higher rheumatology medication expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing adoption of gene therapy is expected to significantly boost the growth of the familial Mediterranean fever (FMF) pharmaceuticals market. Gene therapy is a medical approach that alters or replaces defective genes to treat or prevent diseases at the genetic level. The rise in gene therapy is fueled by advancements in genetic engineering, which allow for precise targeting and correction of genetic disorders, offering potential cures for conditions previously considered untreatable. In the case of familial Mediterranean fever (FMF), gene therapy targets the root cause mutations in the MEFV (Mediterranean fever) gene, potentially offering a long-term or permanent cure rather than merely managing symptoms. For example, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, marking a 25% increase from the previous quarter. As a result, the rise in gene therapy is driving the growth of the FMF pharmaceuticals market.

Leading companies in the familial Mediterranean fever (FMF) pharmaceuticals market are focusing on developing advanced treatments, including cost-effective generic alternatives, as well as exploring novel biologics and gene therapies. A cost-effective generic alternative is a lower-cost version of a branded drug that retains the same active ingredients, dosage, safety, and effectiveness. For example, in January 2022, Camber Pharmaceuticals Inc., a US-based pharmaceutical manufacturing company, introduced generic Colcrys (colchicine) tablets, expanding its product portfolio. These tablets are used to treat and prevent FMF in both adults and children aged four and older, as well as for managing gout flare-ups. The tablets, available in 0.6 mg strength, come in 30- and 100-count bottles. This launch aligns with Camber’s commitment to providing high-quality, affordable generic medications to improve patient care.

In January 2024, Swedish Orphan Biovitrum AB (Sobi), a Sweden-based manufacturer of Interleukin-1 inhibitors, entered into a partnership with Acino International AG. This partnership grants Acino the exclusive rights to distribute Sobi’s specialized rare disease treatments in Kazakhstan, thereby expanding access to innovative therapies. Acino International AG, a Swiss-based pharmaceutical company, specializes in the development, manufacturing, and distribution of high-quality generic and specialty medicines.

Major players in the familial mediterranean fever pharmaceuticals market are Merck & Co. Inc., Bristol Myers Squibb, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Swedish Orphan Biovitrum AB (Sobi), Granules Pharmaceuticals Inc., Sanmar Group, Indena S.p.A., Harman Finochem, Camber Pharmaceuticals Inc., R-Pharm Group, Alchem International, AdvaCare Pharma USA LLC, ViennaLab Diagnostics GmbH, Honour Lab Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma.

Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial mediterranean fever pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the familial mediterranean fever pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial mediterranean fever pharmaceuticals market consists of sales of NSAIDs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and pain management medications used to manage inflammation and prevent complications in familial mediterranean fever patients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The familial mediterranean fever pharmaceuticals market research report is one of a series of new reports that provides familial mediterranean fever pharmaceuticals market statistics, including familial mediterranean fever pharmaceuticals industry global market size, regional shares, competitors with a familial mediterranean fever pharmaceuticals market share, detailed familial mediterranean fever pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the familial mediterranean fever pharmaceuticals industry. This familial mediterranean fever pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Familial Mediterranean fever (FMF) pharmaceuticals refer to medications used to manage and treat FMF, a genetic disorder marked by recurrent episodes of fever and inflammation, often affecting the abdomen, chest, and joints. The primary goal of these medications is to reduce the frequency and severity of attacks and prevent long-term complications such as amyloidosis.

The main pharmaceuticals used in the treatment of familial Mediterranean fever include colchicine, interleukin-1 inhibitors, and anti-IL-6 drugs. Colchicine is a medication that helps reduce inflammation and prevent flare-ups in conditions such as gout and other inflammatory disorders. It can be administered both orally and via injection and is utilized by various end users, including hospitals, clinical diagnostic laboratories, and other healthcare facilities.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.